Literature DB >> 19843686

Breast cancer recurrence in older women five to ten years after diagnosis.

Jaclyn L F Bosco1, Timothy L Lash, Marianne N Prout, Diana S M Buist, Ann M Geiger, Reina Haque, Feifei Wei, Rebecca A Silliman.   

Abstract

Little is known about the risk of recurrence >5 years after diagnosis among older breast cancer survivors. A community-based population of women >or=65 years diagnosed with early-stage breast cancer who survived disease free for 5 years was followed for 5 additional years or until a diagnosis of breast cancer recurrence, second primary, death, or loss to follow-up. These 5-year disease-free survivors (N = 1,277) had primary breast cancers that were node negative (77%) and estrogen receptor positive or unknown (86%). Five percent (n = 61) developed a recurrence between 5 and 10 years after diagnosis: 25% local, 9.8% regional, and 66% distant. Women who were node positive [hazard ratio (HR), 3.9; 95% confidence interval (95% CI), 1.5-10], had poorly differentiated tumors (HR, 2.5; 95% CI, 0.9-6.6), or who received breast conserving surgery without radiation therapy (HR, 2.4; 95% CI, 1.0-5.8) had higher recurrence rates compared with node negative, well differentiated, and receipt of mastectomy, respectively. Not receiving adjuvant tamoxifen, compared with receiving adjuvant tamoxifen, was also positively associated with late recurrence among women with estrogen receptor-positive/unknown tumors. Although relatively few women experience a late recurrence, most recurrences present as advanced disease, which is difficult to treat in older women. This study of late recurrence emphasizes that the risk, although small, is not negligible even in this group at high risk of death due to competing causes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843686      PMCID: PMC2784208          DOI: 10.1158/1055-9965.EPI-09-0607

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

1.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Recurrences and second primary breast cancers in older women with initial early-stage disease.

Authors:  Ann M Geiger; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Marianne N Prout; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Shelley M Enger; Rebecca A Silliman
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

Review 3.  Building a research consortium of large health systems: the Cancer Research Network.

Authors:  Edward H Wagner; Sarah M Greene; Gene Hart; Terry S Field; Suzanne Fletcher; Ann M Geiger; Lisa J Herrinton; Mark C Hornbrook; Christine C Johnson; Judy Mouchawar; Sharon J Rolnick; Victor J Stevens; Stephen H Taplin; Dennis Tolsma; Thomas M Vogt
Journal:  J Natl Cancer Inst Monogr       Date:  2005

4.  Using probabilistic corrections to account for abstractor agreement in medical record reviews.

Authors:  Timothy L Lash; Matthew P Fox; Soe Soe Thwin; Ann M Geiger; Diana S M Buist; Feifei Wei; Terry S Field; Marianne Ulcickas Yood; Floyd J Frost; Virginia P Quinn; Marianne N Prout; Rebecca A Silliman
Journal:  Am J Epidemiol       Date:  2007-04-03       Impact factor: 4.897

5.  Breast cancer treatment of older women in integrated health care settings.

Authors:  Shelley M Enger; Soe Soe Thwin; Diana S M Buist; Terry Field; Floyd Frost; Ann M Geiger; Timothy L Lash; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

6.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Authors:  S G Hilsenbeck; P M Ravdin; C A de Moor; G C Chamness; C K Osborne; G M Clark
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

8.  Mortality impact of less-than-standard therapy in older breast cancer patients.

Authors:  Marianne Ulcickas Yood; Cynthia Owusu; Diana S M Buist; Ann M Geiger; Terry S Field; Soe Soe Thwin; Timothy L Lash; Marianne N Prout; Feifei Wei; Virginia P Quinn; Floyd J Frost; Rebecca A Silliman
Journal:  J Am Coll Surg       Date:  2007-10-03       Impact factor: 6.113

9.  Mammography surveillance and mortality in older breast cancer survivors.

Authors:  Timothy L Lash; Matthew P Fox; Diana S M Buist; Feifei Wei; Terry S Field; Floyd J Frost; Ann M Geiger; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

10.  Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study.

Authors:  Soe Soe Thwin; Kerri M Clough-Gorr; Maribet C McCarty; Timothy L Lash; Sharon H Alford; Diana S M Buist; Shelley M Enger; Terry S Field; Floyd Frost; Feifei Wei; Rebecca A Silliman
Journal:  BMC Med Res Methodol       Date:  2007-06-18       Impact factor: 4.615

View more
  19 in total

1.  Contralateral Breast Cancer Event Detection Using Nature Language Processing.

Authors:  Zexian Zeng; Xiaoyu Li; Sasa Espino; Ankita Roy; Kristen Kitsch; Susan Clare; Seema Khan; Yuan Luo
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  The impact of primary care physicians on follow-up care of underserved breast cancer survivors.

Authors:  Rose C Maly; Yihang Liu; Allison L Diamant; Amardeep Thind
Journal:  J Am Board Fam Med       Date:  2013 Nov-Dec       Impact factor: 2.657

3.  Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.

Authors:  Jayeon Kim; Volkan Turan; Kutluk Oktay
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

4.  Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Authors:  Candyce H Kroenke; Carol Sweeney; Marilyn L Kwan; Charles P Quesenberry; Erin K Weltzien; Laurel A Habel; Adrienne Castillo; Phillip S Bernard; Rachel E Factor; Lawrence H Kushi; Bette J Caan
Journal:  Breast Cancer Res Treat       Date:  2014-03-07       Impact factor: 4.872

5.  Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.

Authors:  Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

Review 6.  Cancer research network: using integrated healthcare delivery systems as platforms for cancer survivorship research.

Authors:  Larissa Nekhlyudov; Sarah M Greene; Jessica Chubak; Borsika Rabin; Leah Tuzzio; Sharon Rolnick; Terry S Field
Journal:  J Cancer Surviv       Date:  2012-12-14       Impact factor: 4.442

7.  Protocol and recruitment results from a randomized controlled trial comparing group phone-based versus newsletter interventions for weight loss maintenance among rural breast cancer survivors.

Authors:  Christie A Befort; Jennifer R Klemp; Carol Fabian; Michael G Perri; Debra K Sullivan; Kathryn H Schmitz; Francisco J Diaz; Theresa Shireman
Journal:  Contemp Clin Trials       Date:  2014-01-31       Impact factor: 2.226

8.  The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival.

Authors:  B B Oven Ustaalioglu; O Balvan; A Bilici; A Develi; M Aliustaoglu; F A Vardar; B Erkol
Journal:  Clin Transl Oncol       Date:  2015-06-17       Impact factor: 3.405

9.  Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

Authors:  Jennifer H Jordan; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Terry S Field; Reina Haque; Pamala A Pawloski; Hans V Petersen; Marianne N Prout; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman; Ann M Geiger
Journal:  Breast Cancer Res Treat       Date:  2014-06-18       Impact factor: 4.872

Review 10.  Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Authors:  Zhuo Li; Yibin Kang
Journal:  Pharmacol Ther       Date:  2016-03-19       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.